Stem Cell TV | Video / Media News

Page 1,445«..10 20..1,4441,4451,446 1,447..1,450 1,460..»

Blood and Bone Marrow Transplant – Nebraska Med

Posted: June 18, 2018 at 5:46 pm

Nebraska Medicine's Blood and Bone Marrow Transplant program has been ranked as one of the busiest adult and pediatric stem cell transplantprograms in the world. The program averages 150 transplants a year since its inception in 1983. Each year, hundreds of patients from across the globe select the world-renowned specialists at Nebraska Medicine to guide their cancer treatment and transplant.

The Bloodand Bone Marrow Transplant team treats adult and pediatric conditions such as leukemia, lymphoma, myelomaand other hematologic cancers, pediatric solid tumors like neuroblastoma or select brain tumors, immune deficiencies like SCID, metabolic diseases, and non-malignant hematologic disorders like sickle cell anemia.

Autologous (aw-tall-o-gus) transplant is the term used when a patients own bone marrow or peripheral blood stem cells. The patient will donate the stem cells before radiation and chemotherapy for infusion later in the treatment process.

Allogeneic (al-lo-jen-a-ick) transplant is the term used when the transplanted bone marrow or peripheral blood stem cells are collected from a person specifically typed and matched with the patient. Usually this is a relative such as a brother or sister, known as a related transplant. In some instances the donor may be an individual from the National Marrow Donor Program; when this is the case, it is called an unrelated transplant. If an autologous transplant is being done stem cells will be specially prepared, preserved and then frozen. These cells will then be carefully thawed prior to infusion during the transplant.

Syngeneic is the term used when stem cells are received from an identical twin.

Our world-renowned experts have been recognized internationally for pioneering a number of ground-breaking advancements that have helped improve success rates andmade blood and bone marrow transplants a more viable and promising option for a growing number of patients.

These advancements have included:

Our doctorsand transplant nurse case managersfollow the patient throughout the entire transplant. This teamspecializes in disease-specific areas and will follow you throughout your entire pre-transplant, transplant and recovery process. Services include a 24/7 infusion center to quickly evaluate and treat patients. This means a better continued quality of care for you.

Nebraska Medicine's cancer (oncology) team is extremely active in clinical research and clinical trials, providing you with access to the most up-to-date and revolutionary treatments.

We are part of the National Institutes of Health/National Cancer Institute Blood and Marrow Transplant Clinical Trials Network a consortium transplant centers across the country that collaborate on clinical trials in order to derive data from a larger population of patients and to allow for greater sharing of information between centers.

Through this network, doctors can study and refine their techniques to diagnose, treat and follow patients to provide them with optimal care.

Our doctorsand scientists are internationally known for their research in this area and offer you access to the newest and most innovative therapies through our participation in blood and bone marrow clinical trials. See what clinical trials related to transplants are currently underway.

Addressing a patients physical, educational, emotional and spiritual needs are important aspects of providing a more complete and holistic approach to care. A host of amenities and supportive services are available to help meet these needs. This includes personal care services such as wigs, wigfittings,prosthetic and brafittings, yoga, massage therapy,skin care and make-uplessons specifically geared for people with or recovering from cancer are also provided in a private setting.

Finding out that you have cancer can be a very emotional and difficult time. You will likely have many questions and issues to work through. We will be with you every step of the way. Nebraska Medicine offers a host of cancer support services to help you with your physical, emotional, educational and financial needs.

Our SurvivorshipClinic is designed to helpadult patientsdeal with the emotional and physical challenges cancer can leave behind such as fear of recurrence, physical and medical long-term side effects and helping you return to a normal life again. It will also help you transition back into the care of your primary care physician.

Blue Distinction Centers and Blue Distinction Centers+ have a proven history of delivering exceptional care and results. Nebraska Medicine has received Blue Distinction in adultand pediatric bone marrow/stem cell patient care.

FACT Accreditation demonstrates our commitment to quality in cellular therapy and blood and marrow transplantation and verifies that our transplant program has met rigorous international standards.

The PBMTC is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents. Our consortium includes over 100 member pediatric BMT centers in the US, Canada, New Zealand, Australia, Thailand and the Czech Republic and over 600 individual members.

See the rest here:
Blood and Bone Marrow Transplant - Nebraska Med

Posted in Nebraska Stem Cells | Comments Off

Hormone Replacement Therapy (Risks and Benefits). HRT …

Posted: June 18, 2018 at 5:46 pm

Approximately 80% of menopausal women experience symptoms. While a quarter of those are thought to have severe symptoms, only a small proportion of menopausal women currently take hormone replacement therapy (HRT).

Symptoms of the menopause last far longer than most women anticipate. Frequent menopausal vasomotor symptoms, including night sweats and hot flushes, persist in more than half of women for more than seven years[1].

HRT is an effective treatment for the typical menopause-related symptoms. There are also other long-term health problems associated with the menopause - the risk of osteoporosis, cardiovascular disease and stroke all increase after the menopause. HRT can also have a positive influence on these health problems.

This article discusses HRT in detail. The separate Menopause and its Management article discusses menopausal symptoms, differential diagnosis and possible investigations (although the diagnosis is usually clinically based on the typical symptoms). It also discusses health problems associated with the menopause and gives an overview of management.

See also separate HRT - Initial Consultation, HRT - Follow-up Assessments and HRT - Topical articles.

Current guidelines advise that HRT should be considered for troublesome vasomotor symptoms in perimenopausal and early postmenopausal women without contra-indications and after individualised discussion of likely risks and benefits[2].

Starting HRT in women over the age of 60 years is generally not recommended.

For women with premature (age <40 years) or early (<45 years) menopause, current guidelines recommend sex steroid replacement until the age of 51 years for the treatment of vasomotor symptoms and for bone and cardiovascular protection[2, 3].

Current indications for the use of HRT are:

The benefits of HRT outweigh the risks for many women aged under 60 years[2, 4].

Benefits of HRT include:

Reduction in vasomotor symptoms

Improvement in quality of lifeHRT can also improve sleep, muscle aches and pains and quality of life in symptomatic women.

Improvement in mood changes

Improvement of urogenital symptoms

Reduction in osteoporosis risk

Reduction in cardiovascular disease

Lower risk of colorectal cancer

Other benefits

The principal risks of HRT are thromboembolic disease (venous thromboembolism (VTE) and pulmonary embolism), stroke, breast and endometrial cancer, and gallbladder disease.

Large studies, including the WHI and the Million Women Study (MWS), raised concerns and controversy over the use of HRT[18, 26].

However, data accumulated from the WHI and other studies over a period of a decade have shown that, in women with symptoms or other indications, initiating HRT near menopause usually provides a favourable benefit:risk ratio[2].

VTE[2]

StrokeThe risk of ischaemic (but not haemorrhagic) stroke[2]:

Breast cancer

NB: there is no evidence of an increased risk of breast cancer in women on HRT under the age of 51 years compared with menstruating women of the same age.

Endometrial cancer

Ovarian cancer

Investigations are not usually necessary before starting HRT unless:

It is important that an individualised approach is undertaken at all stages of diagnosis, investigation and management of menopause[2].

The dose, regimen and duration of HRT need to be individualised. There is no maximum duration of time for women to take HRT. Discussion with women who continue to have symptoms generally show their benefits from HRT usually outweigh any risks. Systemic HRT should not be arbitrarily stopped at age 65 years; instead treatment duration should be individualised based on patients' risk profiles and personal preference[35].

Micronised progesterone is a natural, 'body-identical' progestogen, devoid of any androgenic as well as glucocorticoid activities but being slightly hypotensive due to anti-mineralocorticoid activity. It may be the optimal progestogen in terms of cardiovascular effects, blood pressure, VTE, probably stroke and even breast cancer but this evidence is only from observational studies[36]. There is only one currently available to prescribe in the UK.

As transdermal oestrogen is associated with fewer risks than oral HRT, a transdermal route may be preferable for many women. This route is also advantageous for women with diabetes, history of VTE and also those with thyroid disorders. In addition, transdermal HRT is preferable to those women with a history of migraine or gallbladder problems.

Delivery routes include:

The choice of delivery route depends partly on patient preference but there are also other advantages to certain delivery routes.

By avoiding the first pass metabolism through the liver, non-oral preparations (ie patches or gels):

Other considerations

See separate HRT - Follow-up Assessments article for a discussion of how to manage these side-effects.

See separate HRT - Initial Consultation article.

Follow this link:
Hormone Replacement Therapy (Risks and Benefits). HRT ...

Posted in Hormone Replacement Therapy | Comments Off

Biotechnology Conferences | Biotechnology Conferences 2018 …

Posted: June 18, 2018 at 5:46 pm

Sessions and Tracks

Track 1:Pharmaceutical Biotechnology and Drug Design

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs. Pharmaceutical companies use biotechnology for manufacturing drugs, pharmacogenomics, gene therapy, and genetic testing. Biotech companies make biotechnology products by manipulating and modifying organisms, usually at molecular level. Pharmaceutical Biotechnology is an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs, diagnostic agents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes in healthcare practices and a significant contribution to the development of national economy. Euro Biotechnology 2018 will focus on Biopharmaceuticals Discovery, Biopharmaceutical Regulations and Validations, Biologics and Biosimilars and Clinical Research/Clinical trials, Biotechnology Conferences.

7th World Congress on Mass Spectrometry June 20-22, 2018 Rome, Italy ; 23rd International Pharmaceutical BiotechnologyConferences December 10-11, 2018 Rome, Italy ; 18th World Pharma Congress October 18-20, 2018 Warsaw, Poland ;16th International Conference and Exhibition on Pharmaceutical Formulations July 26-27, 2018 Rome, Italy ; 17th Annual Congress on Pharmaceutics & Drug Delivery Systems September 20-22, 2018 Prague, Czech Republic;16th Annual European Pharma Congress May 20-21, 2019 Zurich, Switzerland ; Pharma Serialisation Summit June 19-21, 2018 Zurich, Switzerland ; European Congress on Pharma August 13-14 , 2018 Paris, France ; Pharma R&D March 04-06, 2019 Paris, France ; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand; 18th European Conferences on Biotechnology July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 2 : Microbial Biotechnology

Microbial biotechnology, enabled by genome studies, will lead to breakthroughs such as improved vaccines and better disease-diagnostic tools, improved microbial agents for biological control of plant and animal pests, modifications of plant and animal pathogens for reduced virulence, development of new industrial catalysts and fermentation organisms, and development of new microbial agents for bioremediation of soil and water contaminated by agricultural runoff,Biotechnology Conferences.

Annual Industrial Biotechnology and Bioprocessing Congress September 17-18, 2018 San Diego, California, USA; 3th International Conference on Microbial Interactions & Microbial Ecology July 19-20, 2018 Rome, Italy; Applied Microbiology October 15-16, 2018 Ottawa, Canada and Microbial Biotechnology October 15-16, 2018 Ottawa, Canada ; 12th World Congress on Biotechnology June 28-29, 2018 Amsterdam, Netherlands and 12th World Congress on Microbiology June 28-29, 2018 Amsterdam, Netherlands ; European Congress on Pharma August 13-14 , 2018 Paris, France ; Pharma R&D March 04-06, 2019 Paris, France ; 6thAsia Pacific Biotechnology ConferencesAugust 15-16, 2018 Singapore; 22ndWorld Congress on BiotechnologyJuly 10-11, 2018Bangkok,Thailand;18thEuropean Conferences on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences; 5th World Congress on Microbial Biotechnology September 17-18, 2018 Lisbon, Portugal,

Related Societies:

Europe:

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Track 3: Nano Biotechnology

Nano Biotechnology is a discipline in which tools from nanotechnology are developed and applied to study biological phenomena. Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology,Biotechnology Conferences.

8th International Conference and Expo on Nanosciences Nov 26-28,2018 Barcelona, Spain; 24th World Nano Conference May 07-08, 2018 Rome, Italy; World Congress on Nano medicine September 17-19, 2018 Abu Dhabi, UAE; World Congress on Nanotechnology in Healthcare September 17-19, 2018 Abu Dhabi, UAE; Advanced Nanotechnology October 04-05 2018 Moscow, Russia; 8th International Conference and Expo on Nanotechnology Nov 26-28,2018 Barcelona, Spain ; International Conference On Nanomedicine And Nanobiotechnology September 26-28, 2018 Rome ; Nanotech & Nanobiotechnology July 12-13, 2018 Paris, France ; 4th International Conference On Nanobiotechnology April 9 - 11, 2019 Rome, Italy, 18thEuropean Congress on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 4: Stem Cell Biotechnology and Regenerative Medicine

Stem cell biotechnology is a field of biotechnology that develops tools and therapeutics through modification and engineering of stem cells. Stem cell biotechnology is important in regenerative medicine. Regenerative medicine is an Inter disciplinary branch that tends to repair or regenerate damaged cells or tissues to regain or restore their normal function,Biotechnology Conferences.

12th Annual Conference on Stem Cell and Regenerative Medicine June 04-06, 2018 Prague, Czech Republic ; 10th Annual Conference on Stem Cell and Regenerative Medicine October 08-09, 2018 Zurich, Switzerland ; World Congress and Expo on Cell & Stem Cell Research September 13-15, 2018 Paris, France ; 11th Annual Conference on Stem Cell and Regenerative Medicine October 15-16, 2018 Helsinki, Finland ; International Conference On Cell and Stem Cell Research August 17-18, 2018 Singapore ; Modeling Cell-Cell Interactions Governing Tissue Repair and Disease August 19 - 24, 2018 ; Stem Cell Conference Basel 2018 August 29-31, 2018 Basel, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferencesJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 5: Medical Biotechnology

Medical Biotechnology is the use of living cells and cell materials to research and produce pharmaceutical and diagnostic products that help treat and prevent human diseases. leading to the development of several innovative techniques for preventing, diagnosing, and treating diseases,Biotechnology Conferences.

11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy; 12th World Conference on Human Genomics and Genomic MedicineApril 22-23, 2019 Abu Dhabi, UAE; 4th International Conference on Advances in Biotechnology and Bioscience November 15-17, 2018 Frankfurt, Germany ; 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy ; Medical Biotechnology May 24-25, 2018 Ghent, Belgium ; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand,18th European BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 6: Oncolytic Biotechnology

Oncolytic Biotechnology is the study of oncolytic virus, the virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune responses,Biotechnology Conferences.

11th International Virology and Microbiology July 27-28, 2018 Vancouver, Canada ; 11th World Congress on Virology and Infectious Diseases May 17-18, 2018 Tokyo, Japan ; 2nd International Conference on Cancer Biology, Therapeutics and Drug Discovery & Delivery October 03-04, 2018 Los Angeles, California, USA ; Beatson International Cancer Conference July 01- 04, 2018 Glasgow, Scotland ; 36th World Cancer Conference October 11-13, 2018 Zurich, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 7: Molecular Biotechnology and Genetics

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product. The tools of molecular biotechnology can be applied to develop and improve drugs, vaccines, therapies, and diagnostic tests that will improve human and animal health. Molecular biotechnology has applications in plant and animal agriculture, aquaculture, chemical and textile manufacturing, forestry, and food processing.

Biochemistry & Molecular Biology October 11-12, 2018 Amsterdam, Netherlands ; International Conference on Molecular Biology and Medicine August 27-28, 2018 Dubai, UAE ; World Congress on Advanced Structural and Molecular Biology 2018 August 22-23, 2018 Rome, Italy ; World Congress on Plant Science and Molecular Biology September 12-13, 2018 Singapore ; 6th Annual Congress on Medicine of Molecules September 17-18, 2018 Abu Dhabi, UAE; 10th Annual Conference on Stem Cell October 08-09, 2018 Zurich, Switzerland; 10th Annual Conference on Stem Cell Regenerative Medicine October 08-09, 2018 Zurich, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferencesJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 8: Environmental Biotechnology

Environment biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. It is "the development, use and regulation of biological systems for remediation of contaminated environment and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process.

36th International Conference on Environmental Chemistry & Water Resource Management September 24-25, 2018 Chicago, Illinois, USA; 20th International Conference on Environmental Biotechnology and Bioremediation January 15 - 16, 2018 Zurich, Switzerland; International Society for Environmental Biotechnology June 25-28, 2018 Chania, Greece; 10th Annual Conference on Stem Cell Regenerative Medicine October 08-09, 2018 Zurich, Switzerland; 6th Annual Congress on Biology, 6th Annual Congress on Medicine of Molecules September 17-18, 2018 Abu Dhabi, UAE; 8th International Conference and Expo on Nanosciences Nov 26-28,2018 Barcelona, Spain; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 9: Plant and Forest Biotechnology

Plant Biotechnology is a set of techniques used to adapt plants for specific needs or opportunities. Situations that combine multiple needs and opportunities are common, it is prominent in the field of medicine interfacing biotechnology and bioinformatics, the molecular characterization of medicinal plants; molecular farming; and result from chemistry, nanotechnology, pharmacology, agriculture, Biomass and biofuels as well. Plant Biotechnology is the technology which is used for getting modern product with high yield and at faster rate. Biotechnology is being used as a tool to grow trees with special characteristics. When used responsibly, society and the environment can benefit from advanced tree breeding technologies.

World congress on Plant Pathology & Plant Biotechnology September 24- 25, 2018 Dallas, USA; Agriculture & Horticulture April 08-09, 2019 Prague, Czech Republic; 6th Global Summit on Plant Science October 29-30, 2018 Valencia, Spain; International Association For Plant Biotechnology ConferencesAugust 19-24, 2018 Dublin, Ireland ; Plant Metabolic Engineering Jun 15-16, 2019 Lucca (Barga), Italy. 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean Congress on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

USA:

Asia:

Track 10: Food and Feed Biotechnology

See the rest here:
Biotechnology Conferences | Biotechnology Conferences 2018 ...

Posted in Biotechnology | Comments Off

Plant Biology Conferences 2019 | Plant Biotechnology …

Posted: June 18, 2018 at 5:46 pm

Past Conference Information

GlobalConference onPlant ScienceandMolecular Biology2017Report:

Magnus Grouptakes a great pride in declaring the GlobalConference on Plant Science and Molecular Biology (GPMB 2017) which was held in Valencia, Spain, during September 11-13, 2017.

Plant Science Conference 2017witnessed an amalgamation of outstanding speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Plant Science and Molecular Biology. The extremely well-known conference hosted by Magnus Group was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing diverse countries around the world.

For GPMB 2017 Final Program:Click Here

The theme of the conference is Accentuate Innovations and Emerging Novel Research in Plant Sciences. The meeting captivated a vicinity of utilitarian discussions on novel subjects like Plant Physiology and Biochemistry, Plant Biotechnology, Plant Pathology: Mechanisms Of Disease, Applications In Plant Sciences And Plant Research, to mention a few. The three days event implanted a firm relation of upcoming strategies in the field of Plant Science and Molecular Biology with the scientific community. The conceptual and pertinent knowledge shared, will correspondingly foster organizational collaborations to nurture scientific accelerations.

For GPMB 2017 Gallery:Click Here

GPMB 2017Organizing Committee

Prof. Ammann Klaus, University of Bern, Switzerland

Prof. Leif Sundheim, Norwegian Institute of Bioeconomy Research, Norway

Prof. Cornelia Butler Flora, Kansas State University, USA

Dr. Monica Ruffini Castiglione, University of Pisa, Italy

Dr. Samir C. Debnath, St. Johns Research and Development Centre, Canada

The Organizing Committee would like to thank the moderatorsDr. Victoria A Piunova, IBM Almaden Research Center, United States, Dr. Selcuk Aslan, Max Planck Institute of Molecular Plant Physiology, Germany and Dr. Susan Yvonne Jaconis, CSIRO Agriculture, Australia for their contributions which ensued in smooth functioning of the conference.

The highlights of the conference were the keynote forum by prominent scientists,Prof. Klaus Ammann, University of Bern, Switzerland; Prof. Cornelia Butler Flora, Kansas State University, USA; Dr. Monica Ruffini Castiglione, University of Pisa, Italy; Prof. Leif Sundheim, Norwegian Institute of Bioeconomy Research, Norway; Dr. Samir C. Debnath, St. Johns Research and Development Centre, Canada; Dr. Goutam Gupta, Los Alamos National Laboratory, USA; Dr. Elena Rakosy-Tican, Babes-Bolyai University, Romania; Dr. Ivica Djalovic, Institute of Field and Vegetable Crops, Serbia; gave their fruitful contributions in the form of very informative presentations and made the conference a top notch one.

Magnus Groupis privileged to thank the Organizing Committee Members, Keynote speakers, Session chairs on transcribing the sessions, in a varied and variegate manner to make this conference a desirable artifact.

Speakers of GPMB 2017

Day 1: Speakers

Antonova Galina Feodosievna, VN Sukachev Institute of Forest Siberian Branch of Russian Academy of Sciences, Russian Federation

Cezary Piotr Sempruch, Siedlce University of Natural Sciences and Humanities, Poland

Ivan Paponov, Norwegian Institute of Bioeconomy Research, Norway

Malgorzata Adamiec, Adam Mickiewicz University, Institute of Experimental Biology, Poland

Michael Handford, Universidad de Chile, Chile

Natalia Repkina, Institute of Biology Karelian Research Centre of the Russian Academy of Sciences, Russia

Elide Formentin, University of Padova, Italy

Magdalena Opalinska, University of Wroclaw, Poland

Moses Kwame Aidoo, Ben-Gurion University of the Negev, Israel

Yuke He, Shanghai Institutes for Biological Sciences, China

Sameera Omar Bafeel, King Abdulaziz University, Science college, Saudi Arabia

Joerg Fettke, University of Potsdam, Germany

Siti Nor Akmar Abdullah, Universiti Putra Malaysia, Malaysia

Alberto Guillen Bas, University of Valencia, Spain

Carmen Quinonero Lopez, University of Copenhagen, Denmark

Laura Fattorini, Sapienza University of Rome, Italy

Meltem Bayraktar, Ahi Evran University, Turkey

Victoria Cristea, Babes-Bolyai University Cluj-Napoca, Romania

Selcuk Aslan, Max Planck Institute of Molecular Plant Physiology, Germany

Sofia Kourmpetli, Cranfield Soil and AgriFoodInstitute, UK

Seanna Hewitt, Washington State University, USA

Javier Terol Alcayde, Centro de Genomica, IVIA , Spain

Susan Yvonne Jaconis, CSIRO Agriculture, Australia

Magdalena Szechynska-Hebda, Institute of Plant Physiology, Polish Academy of Sciences, Australia

Acga Cheng, University of Malaya, Malaysia

Henrik Toft Simonsen, Technical University of Denmark, Denmark

Yeyun Xin, China National Hybrid Rice Research and Development Center, China

Sandhya Mehrotra, Birla Institute of Technology and Science Pilani, India

Gustavo Souza, Federal University of Pernambuco Bioscience Center, Brazil

Rachel Swee-Suak Ko, Academia Sinica, ABRC/BCST, Taiwan, Province of China

Yougasphree Naidoo, School of Life Sciences, South africa

Julian Witjaksono, The Assessment Institute for Agricultural Technology of Souhteast Sulawesi, Indonesia

Day-1 Posters

Lingling Shang, The Faculty of Agriculture and Food Sciences, Laval University, Canada

Nahaa Miqad Alotaibi, Swansea University, United Kingdom

Layla Al Hijab, West of England Universtiy, United Kingdom

Tomasz Goral, Plant Breeding and Acclimatization Institute NRI, Poland

Mikhail Oliveira Leastro, Instituto Biologico de Sao Paulo, Brazil

Michael Handford, Universidad de Chile, Chile

Polzella Antonella, University of Molise, Italy

Wisniewska Halina, Institute of Plant Genetics Polish Academy of Sciences, Poland

Costel Sarbu, Babes-Bolyai University Cluj-Napoca, Romania

Benjamin Dubois, Walloon Agricultural Research Center (CRA-W), Belgium

Sandra Cichorz, Plant Breeding and Acclimatization Institute - NRI, Poland

Elzbieta Kochanska-Czembor, Plant Breeding and Acclimatization Institute, Poland

Woo Taek Kim, Yonsei University, Republic of Korea

Prashanth Tamizhselvan, Masaryk University, CEITEC MU, Czech Republic

Yun Hee Kim, Gyeongsang National University, Republic of Korea

Nada Bezic, University of Split, Croatia

Havrlentova Michaela, Research Institute for Plant Productio, Slovakia

Seok Keun Cho, Yonsei University, Republic of Korea

Prasanna Angel Deva, Ben Gurion University of the Negev, Israel

Kebede Mesfin Haile, Kangwon National University, Korea

Lidia Kowalska, Plant Breeding and Acclimatization Institute, Poland

Motyleva Svetlana Mikhailivna, FSBSI ARHIBAN, Russian Federation

Paulina Drozdz, Forest Research Institute, Poland

Chul Han An, Korea Research Institute of Bioscience and Biotechnology, Republic of Korea

Jurga Jankauskiene, Nature Research Centre, Lithuania

Day 2: Speakers

Victoria A Piunova, IBM Almaden Research Center, United States

Miroslava Cuperlovic-Culf, National Research Council Canada, Canada

Paola Leonetti, IPSP-CNR, Italy

Giulia Chitarrini, Fondazione Edmund Mach, Italy

Antonio Domenech-Carbo, University of Valencia, Spain

Nurshafika Mohd Sakeh, Universiti Putra Malaysia, Malaysia

Adel Saleh Hussein Al-Abed, National Center for Agricultural Research and Extension, Jordan

Manju Sharma, Amity Institute of Biotechnology, India

Sergio Molinari, IPSP-CNR, Italy

Jaroslava Ovesna, Crop Research institute, czech Rpublic

John B. Carrigan, RebelBio SOSV, Ireland

Bardouki Haido, VIORYL S.A., Greece

Natalia Tomas Marques, Universidade do Algarve, Portugal

Azza M. Salama, Cairo University, Egypt

Chang-Yoon JI, University of Science & Technology, Korea

Kgabo Martha Pofu, Agricultural Research Council, South Africa

Siegfried Zerche, Leibniz-Institute of Vegetable- & Ornamental Crops, Germany

Piergiorgio Stevanato, University of Padova, Italy

Seong Wook Yang, Yonsei University, Republic of Korea

Alexander Hahn, Max Planck Institute for Biophysic, Germany

Klaus Harter, University of Tuebingen, Center for Plant Molecular Biology, Germany

Laigeng Li, Institute of Plant Physiology and Ecology, China

Thomas C Mueller, University of Tennessee, United States

Read the original post:
Plant Biology Conferences 2019 | Plant Biotechnology ...

Posted in Biotechnology | Comments Off

Fasting for 24 hours regenerates stem cells, study finds …

Posted: June 18, 2018 at 5:46 pm

Fasting has long-held associations with mental and bodily repair, from religionasceticism to detox diets. A new study points to one reason fasting may be good for our bodies, with evidence that a 24-hour gap in eating can flick a metabolic switch for regeneration in our digestive system.

By studying the effects of fasting on mice, a team of researchers at MIT found that just one day of calorie restriction substantially improves the ability for stem cells in the intestine to regenerate. Not only does this underline the beneficial effects of short periods of fasting, but it could also pave the way for drugs that stimulate the effects in cancer patients.

As we get older, our intestinal cells get worse at regenerating, meaning our bodies are less able to fight off infections and diseases in our gut. In the fasting mice, however, cells began to break down fatty acids instead of glucose. This stimulated the stem cells to become more regenerative.

This study provided evidence that fasting induces a metabolic switch in the intestinal stem cells, from utilising carbohydrates to burning fat, says David Sabatini, an MIT professor of biology and senior author of the paper, published in Cell Stem Cell.

Interestingly, switching these cells to fatty acid oxidation enhanced their function significantly. Pharmacological targeting of this pathway may provide a therapeutic opportunity to improve tissue homeostasis in age-associated pathologies.

(Intestinal organoidsfrom mice that fasted for 24 hours (R) and from mice that did not fast (L).Credit: Maria Mihaylova and Chia-Wei Cheng)

The scientists took samples of the mices intestinal cells after a period of 24-hour fasting, then grew them in the lab to determine their ability to produce an organoid, in this case a kind of mini-intestine. They found that the regenerative capacity of the mice that had fasted was double that of mice that hadnt fasted.

It was very obvious that fasting had this really immense effect on the ability of intestinal crypts to form more organoids, which is stem-cell-driven, said lead author, Maria Mihaylova. This was something that we saw in both the young mice and the aged mice, and we really wanted to understand the molecular mechanisms driving this.

To glean the reasons for the increased regeneration, the researchers sequenced the messenger RNA of the stem cells, and found that fasting flips a switch by activating transcription factors called PPARs, which turned on genes involved with metabolising fatty acids. The result is the cell metabolises fatty acids instead of carbohydrates.

Crucially, the scientists found they could imitate this effect with a molecule that mimics the effects of the PPARs. This suggests that drug treatment could one day be developed to similarly flip the metabolic switch, and help regeneration in the intestine. This could have massive benefits for the elderly, and for cancer patients receiving chemotherapy, which tends to harm cells in the digestive system.

In a beautiful set of experiments, the authors subvert the system by causing [] metabolic changes without fasting and see similar effects, says Jared Rutter, a professor of biochemistry at the University of Utah School of Medicine, who wasnt involved in the research.

This work fits into a rapidly growing field that is demonstrating that nutrition and metabolism [have] profound effects on the behavior of cells and this can predispose for human disease.

See the article here:
Fasting for 24 hours regenerates stem cells, study finds ...

Posted in Utah Stem Cells | Comments Off

Frequently Asked Questions | Stem Cell Of America

Posted: June 18, 2018 at 5:46 pm

Does the Stem Cell treatment have any age requirements?

No, Stem Cell Of America accepts patients of all ages.

There are multiple factors in determining the cost of treatment. Please contact us to have your case evaluated.

No, the treatment is not covered by private or public health insurance.

Yes, we routinely accept patients from Canada, England, Australia and other countries all over the world.

Yes, the cells are tested for 14 different criteria, including viral, bacterial, and fungal infections, as well as viability. Moreover, we use PCR DNA testing, which is far more sophisticated and expensive than the screening tests routinely used in the United States for other Stem Cell treatments.

No, Fetal Stem Cellsare immune privileged. This means that you can give the cells to any patient without matching, use of immunosuppressive drugs and without rejection. Therefore they will not cause adverse reactions in the patient, such as graft-versus-host disease. Because of this special property of the cells there is no risk of rejection or adverse reaction, which can leave the body vulnerable to serious diseases and infection.

Our Fetal Stem Cell treatment has no known negative side effects.

A partial list of disease and conditions that Stem Cell of America has successfully treated includes:

Due to the rapid advances in Stem Cell science, some diseases or conditions may not be listed. Please contact us to get additional information.

Every person is of course different. Each of our bodys healing mechanisms work at a unique pace as they are influenced by many factors. Commonly, significant positive changes are seen between three to six months post treatment. At times, these changes can occur in as little as weeks or even days after receiving treatment.

After the first treatment, the Fetal Stem Cells will continue to proliferate and repair. Some patients choose to receive treatment more than one time to expedite the healing process. The decision is yours. If you decide to repeat the treatment, usually a waiting period of 6 months is recommended.

Fetal Stem Cells are the cellular building blocks of the 220 cell types within the body. The Fetal Stem Cells used by Stem Cell Of America remain in an undifferentiated state and therefore are capable of becoming any tissue, organ or cell type within the body.

Fetal Stem Cells also release Cytokines. Cytokines are cell-derived, hormone-like polypeptides that regulate cellular replication, differentiation, and activation. Cytokines can bring normal cells and tissues to a higher level of function, allowing the bodys own healing mechanisms to partner with the transplanted Fetal Stem Cells for repair and new growth.

In the past 2 decades, Stem Cell Of America has arranged for the treatment of over four thousand patients with Fetal Stem Cells. The number of patients continues to grow. Please contact us to get specific information on a disease or condition.

Stem Cell Of America has offices in the United States and a treatment center in Mexico.

Excerpt from:
Frequently Asked Questions | Stem Cell Of America

Posted in Stem Cell Treatments | Comments Off

Risks of Stem Cell Treatments – StemCultures

Posted: June 18, 2018 at 5:46 pm

Every day sick patients are asking how canstem cell therapy help them now. These patients are most likely desperate for any help, as the current medicine or prognosis just isnt cutting it. And while one daythere may be aviableanswer ofa yes, right now unfortunately, the field isjust not there yet. But, others do not share this view and are in fact offering to cure peoples diseases with stem cell treatments, a phenomenon known as stem cell tourism as most cases occur outside this country. Below we discuss a little about this.

What are stem cell treatments?

As was mentioned, stem cell treatments have been developed as a way to intervene in the development of and potentially treat a whole host of illnesses and physical maladies. These include baldness, missing teeth, and blindness, as well as degenerative illnesses like Parkinsons disease, type 1 diabetes mellitus, heart failure, and even cancer.

The majority of the advertised stem cell treatments utilize adult stem cells, normally harvested from the patient, and these stem cells are introduced into the damaged part of the body. The stem cells then self-renew within the damaged part, promoting growth of new tissues and subsequently replacing the diseased tissues.

Since the stem cells have been harvested from the body of the patient, theoretically, the odds of rejection or fatal side effects are very minimal. Because this is the case, stem cell treatments essentially provide a less invasive, more viable, and more sustainable therapeutic or treatment approach than similar intervention methods like organ transplantation.

Most stem cell treatments are still in the research phase.

Stem cell treatment clinics have been mushrooming everywhere. They are manifold in medical tourism centers in India, China, Ukraine, and Mexico. Even in the United States, where the oversight of the Food and Drug Administration or FDA is strict, stem cell treatment centers operate.

But while this is the case, it is crucial to keep in mind that most stem cell treatments, with the exception of bone marrow transplantation, are still in the preliminary research stages. In fact, studies of these treatments remain so new that finding published results is next to impossible.

Countries like China that study stem cell treatments on a clinical level do not have adequate and up-to-medical-standard documentation processes either, further putting the public in the dark when it comes to stem cell treatments efficacy and dangers.

There are several potential risks of stem cell treatments.

Even aside from the preliminary research phases and lack of published results, stem cell treatments have many risks. And the worst part is studies on these risks, as on the treatments efficacy, are yet to be explored by the medical community.

For instance, in the case of cancer, there is the danger of further aggravating the progress of the disease. Bear in mind that these treatments involve the introduction of stem cells into the diseased part of the body. Sure, the stem cells will most likely be harvested from the same patient and thus not foreign to the recipients body. However, factors such as uncontrolled growth may still occur and therefore further worsen the disease instead of treat it.

Another danger is the unchecked use of the types of stem cells to be administered. In countries without supervision and regulation of these types of intervention strategies, the use of stem cells harvested from sheep and sharks has been reported for treating human patients; an obviously bad situation.

Think twice before choosing stem cell treatments.

While stem cell treatment clinics are popping up all over most of these are scammers who prey on the desperately ill. Another sector has been cropping up offering stem cell treatments for cosmetic purposes as well. With promises of efficient and unfailing treatments, may they be for cosmetics, mild physical maladies, or serious terminal cases, there is no doubt that these treatments can sometimes be tempting to take.

But bear in mind that stem cell treatmentsthe legitimate ones, that isare mostly in the preliminary research stages. Because of this, you wont really be sure whether the treatment you obtain will work or not. And remember, if sounds to good to be true, it probably is. If there was a miracle treatment out there that really does cure horrible diseases, dont you think every sick patient would be getting it done and being healed? For more information, please visit this website put together by the international society for stem cell research: http://www.closerlookatstemcells.org/

If you enjoyed this post, please consider subscribing below to our monthly newsletter through which we provide stem cell scientists information on the most current research topics and tools to help them constantly improve their stem cell culture experience.

To Successful Research,StemCultures

Information for scientists by scientists on all things related to stem cell growth including stem cell culture, culture medium, tissue culture, fibroblast growth factor (fgf2) and more.

Note: StemCultures facilitates posting on this blog, but the views and accounts expressed herein are those of the author(s) or interviewee(s) and not the views or accounts ofStemCultures its officers or directors whose views and accounts may or may not be similar or identical. StemCultures, its officers and directors do not express any opinion regarding any product or service by virtue of reference to such product or service in this blog.

See the original post:
Risks of Stem Cell Treatments - StemCultures

Posted in Stem Cell Treatments | Comments Off

Gene therapy – Mayo Clinic

Posted: June 18, 2018 at 5:44 pm

Overview

Gene therapy involves altering the genes inside your body's cells in an effort to treat or stop disease.

Genes contain your DNA the code that controls much of your body's form and function, from making you grow taller to regulating your body systems. Genes that don't work properly can cause disease.

Gene therapy replaces a faulty gene or adds a new gene in an attempt to cure disease or improve your body's ability to fight disease. Gene therapy holds promise for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.

Researchers are still studying how and when to use gene therapy. Currently, in the United States, gene therapy is available only as part of a clinical trial.

Gene therapy is used to correct defective genes in order to cure a disease or help your body better fight disease.

Researchers are investigating several ways to do this, including:

Gene therapy has some potential risks. A gene can't easily be inserted directly into your cells. Rather, it usually has to be delivered using a carrier, called a vector.

The most common gene therapy vectors are viruses because they can recognize certain cells and carry genetic material into the cells' genes. Researchers remove the original disease-causing genes from the viruses, replacing them with the genes needed to stop disease.

This technique presents the following risks:

The gene therapy clinical trials underway in the U.S. are closely monitored by the Food and Drug Administration and the National Institutes of Health to ensure that patient safety issues are a top priority during research.

Currently, the only way for you to receive gene therapy is to participate in a clinical trial. Clinical trials are research studies that help doctors determine whether a gene therapy approach is safe for people. They also help doctors understand the effects of gene therapy on the body.

Your specific procedure will depend on the disease you have and the type of gene therapy being used.

For example, in one type of gene therapy:

Viruses aren't the only vectors that can be used to carry altered genes into your body's cells. Other vectors being studied in clinical trials include:

The possibilities of gene therapy hold much promise. Clinical trials of gene therapy in people have shown some success in treating certain diseases, such as:

But several significant barriers stand in the way of gene therapy becoming a reliable form of treatment, including:

Gene therapy continues to be a very important and active area of research aimed at developing new, effective treatments for a variety of diseases.

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

Dec. 29, 2017

Here is the original post:
Gene therapy - Mayo Clinic

Posted in Gene therapy | Comments Off

Gene Therapy | Pfizer: One of the world’s premier …

Posted: June 18, 2018 at 5:44 pm

Gene therapy is a technology aimed at correcting or fixing a gene that may be defective. This exciting and potentially transformative area of research is focused on the development of potential treatments for monogenic diseases, or diseases that are caused by a defect in one gene.

The technology involves the introduction of genetic material (DNA or RNA) into the body, often through delivering a corrected copy of a gene to a patients cells to compensate for a defective one, using a viral vector.

Viral vectors can be developed using adeno-associated virus (AAV), a naturally occurring virus which has been adapted for gene therapy use. Its ability to deliver genetic material to a wide range of tissues makes AAV vectors useful for transferring therapeutic genes into target cells. Gene therapy research holds tremendous promise in leading to the possible development of highly-specialized, potentially one-time delivery treatments for patients suffering from rare, monogenic diseases.

Pfizer aims to build an industry-leading gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities, and enhancing those capabilities through strategic collaborations, as well as potential licensing and M&A activities.

We're working to access the most effective vector designs available to build a robust clinical stage portfolio, and employing a scalable manufacturing approach, proprietary cell lines and sophisticated analytics to support clinical development.

In addition, we're collaborating with some of the foremost experts in this field, through collaborations with Spark Therapeutics, Inc., on a potentially transformative gene therapy treatment for hemophilia B, which received Breakthrough Therapy designation from the US Food and Drug Administration, and 4D Molecular Therapeutics to discover and develop targeted next-generation AAV vectors for cardiac disease.

Gene therapy holds the promise of bringing true disease modification for patients suffering from devastating diseases, a promise were working to seeing become a reality in the years to come.

Originally posted here:
Gene Therapy | Pfizer: One of the world's premier ...

Posted in Gene therapy | Comments Off

Are Stem Cells the Future of Hip Replacement? | Plancher …

Posted: October 18, 2017 at 8:09 pm

It looks like traditional hip replacement therapy may soon be a thing of the past. Latest advancements in hip replacement treatments are now focusing the spotlight on stem cells in rebuilding cartilage and restoring bone strength.

For most of our patients here at ourNew York sports medicine practice,

this is certainly good news as the utilization of stem cells in hip replacement is less invasive than traditional treatment methods. In addition, it does not require the use of general anesthesia and can potentially eliminate or reduce risk of infection which is a common adverse effect in any surgical procedure.

The Stem Cell Basics

You probably know by now that the cell is the basic unit of life of each living microorganism, including us, humans. What sets stem cells apart from the rest of the cells in your body is that they are actually unspecialized cells that has the potential to become another type of cell with a specialized function such as a red blood cell, brain cell or a muscle cell given the right experimental or physiologic conditions. By and large, you can consider them akin tosuperheroes who can copy the powers of other superheroes. Cool huh?

There are predominantly 2 basic forms of stem cells the embryonic stem cell and adult stem cell. Embryonic stem cells are derived from human embryos that are developed from eggs fertilized in in vitro fertilization clinics and are donated for research purposes. Embryonic stem cells are not derived from fertilized eggs in a womans body,

The second type of stem cell is the adult stem cell, also known as mesenchymal stem cell or MSC. It is found in tissues and organs such as the bone marrow, skeletal muscle, skin, teeth, heart, gut, liver, peripheral blood, blood vessels, ovarian epithelium, and the testis. This second type of stem cell is commonly used in hip replacement, particularly the ones that are found in the bone marrow.

How It Works

Generally, hip replacement via stem cells involves harvesting the stem cells from the bone marrow through a biopsy needle and then centrifuged for a more concentrated mixture. The resulting mixture of stem cells is then injected into the hip joint, usually followed by an injection of platelet rich plasma which is required to support the growth of cartilage and new hip joint tissues.

Practical Concerns

Practical issues that may arise from stem cell therapy in hip replacement include costs, storage, availability, and regulatory issues. Hence The Plancher Orthopaedics and Sports Medicine team believes that while the research in this area is showing positive results, were still several years away from offering it as an alternative to a hip replacement.

If you have queries concerning the latest in hip replacement therapy such as stem cell treatment, we encourage you to get in touch with us. Wed love to hear from you! Call us at 212-876-5200 orfill out this contact form!

Posted in New York Stem Cells | Comments Off

Page 1,445«..10 20..1,4441,4451,446 1,447..1,450 1,460..»

Blood and Bone Marrow Transplant – Nebraska Med

Hormone Replacement Therapy (Risks and Benefits). HRT …

Biotechnology Conferences | Biotechnology Conferences 2018 …

Plant Biology Conferences 2019 | Plant Biotechnology …

Fasting for 24 hours regenerates stem cells, study finds …

Frequently Asked Questions | Stem Cell Of America

Risks of Stem Cell Treatments – StemCultures

Gene therapy – Mayo Clinic

Gene Therapy | Pfizer: One of the world’s premier …

Are Stem Cells the Future of Hip Replacement? | Plancher …

Categories

Archives

Recommended Sites

Contact Us

Recent Posts